159 related articles for article (PubMed ID: 15983397)
1. Enrichment designs: efficiency in development of cancer treatments.
Temple RJ
J Clin Oncol; 2005 Aug; 23(22):4838-9. PubMed ID: 15983397
[No Abstract] [Full Text] [Related]
2. Improving the evaluation of new cancer treatments: challenges and opportunities.
Rothenberg ML; Carbone DP; Johnson DH
Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
[TBL] [Abstract][Full Text] [Related]
3. Multi-arm clinical trials of new agents: some design considerations.
Freidlin B; Korn EL; Gray R; Martin A
Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials of parenteral antineoplastic agents.
Cusack G
J Intraven Nurs; 1998; 21(6):339-43. PubMed ID: 10392099
[TBL] [Abstract][Full Text] [Related]
5. Newer phase II trial designs gaining ground.
Benowitz S
J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
[No Abstract] [Full Text] [Related]
6. SRC as a potential therapeutic target in solid tumor oncology.
Gallick GE
Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218
[No Abstract] [Full Text] [Related]
7. Vitamin C as a cancer treatment: state of the science and recommendations for research.
Tamayo C; Richardson MA
Altern Ther Health Med; 2003; 9(3):94-101. PubMed ID: 12776480
[No Abstract] [Full Text] [Related]
8. Apathy in geriatric cancer research.
Ault A
Nat Med; 1999 Sep; 5(9):971. PubMed ID: 10471262
[No Abstract] [Full Text] [Related]
9. Cancer treatment and the older patient.
Trimble EL; Christian MC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1956-7. PubMed ID: 16609002
[No Abstract] [Full Text] [Related]
10. Clinical trial design issues in the era of targeted therapies.
Schiller JH
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4281s-4282s. PubMed ID: 15217975
[TBL] [Abstract][Full Text] [Related]
11. Cancer clinical trials: development and implementation.
Vail DM
Vet Clin North Am Small Anim Pract; 2007 Nov; 37(6):1033-57; v. PubMed ID: 17950881
[TBL] [Abstract][Full Text] [Related]
12. Selection of participants for clinical trials in cancer prevention.
Horton J
Semin Oncol; 1983 Sep; 10(3):348-54. PubMed ID: 6665561
[No Abstract] [Full Text] [Related]
13. Evaluation of randomized discontinuation design.
Freidlin B; Simon R
J Clin Oncol; 2005 Aug; 23(22):5094-8. PubMed ID: 15983399
[TBL] [Abstract][Full Text] [Related]
14. The conduct of therapeutic trials in cancer medicine.
Rudnick S; Capizzi RL
Semin Oncol; 1977 Jun; 4(2):255-8. PubMed ID: 327556
[No Abstract] [Full Text] [Related]
15. Celebrating novel cancer drugs.
Weiss RA
Br J Cancer; 2003 Aug; 89(3):425. PubMed ID: 12888806
[No Abstract] [Full Text] [Related]
16. How can we improve clinical trials?
Kaplan RS
Nat Clin Pract Oncol; 2007 Apr; 4(4):206-7. PubMed ID: 17392712
[No Abstract] [Full Text] [Related]
17. Translation of innovative designs into phase I trials.
Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
[TBL] [Abstract][Full Text] [Related]
18. Cancer pharmacogenetics.
Marsh S
Methods Mol Biol; 2008; 448():437-46. PubMed ID: 18370241
[TBL] [Abstract][Full Text] [Related]
19. Using "rationally designed drugs" rationally.
Brugarolas J; Clark JW; Chabner B
Lancet; 2003 May; 361(9371):1758-9. PubMed ID: 12781531
[No Abstract] [Full Text] [Related]
20. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Ratain MJ; Eckhardt SG
J Clin Oncol; 2004 Nov; 22(22):4442-5. PubMed ID: 15483011
[No Abstract] [Full Text] [Related]
[Next] [New Search]
